Announcements Trials

Browse Landscape

Phase

Status

Withdrawn 1 Unknown 1 Terminated 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 2 Skin Neoplasms 1 Sarcoma 1 Prostatic Neoplasms 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Neoplasms 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Diabetes Mellitus, Insulin-Dependent, 12 1 Cholangiocarcinoma 1 Carcinoma, Transitional Cell 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Merkel Cell 1 Carcinoma, Hepatocellular 1 Carcinoma, Basal Cell 1 Breast Neoplasms 1 Autoimmune Diseases 1

Interventions

Dexamethasone 112 Bortezomib 61 Lenalidomide 49 Cyclophosphamide 49 Calcium Dobesilate 43 pomalidomide 32 Melphalan 31 fludarabine 25 Filgrastim 25 carfilzomib 22 fludarabine phosphate 21 daratumumab 20 Granulocyte Colony-Stimulating Factor 16 Whole-Body Irradiation 15 Antilymphocyte Serum 15 dexamethasone acetate 14 Mycophenolic Acid 14 Thalidomide 13 Tacrolimus 13 Cyclosporine 13 Busulfan 13 Peripheral Blood Stem Cell Transplantation 12 ixazomib 11 dexamethasone 21-phosphate 10 auricularum 10 pembrolizumab 9 Radiotherapy 9 Etoposide 9 belantamab mafodotin 8 Rituximab 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Multiple Myeloma × Immunotherapy × Clear all

NCT03634800 2021-08-05

RISE-M

Weill Medical College of Cornell University

Phase 2 Terminated

6 enrolled 11 charts

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡